bioRxiv ScienceSearch

bioRxiv · 10.1101/299214

Human Papillomavirus Type 16 L1/L2 VLP Experimental Internalisation by Human Peripheral Blood Leukocytes

Abstract

Human papillomavirus (HPV) accounts for hundreds of thousands of new cases of cervical cancer yearly, and half of these women die of this neoplasia. This study investigates the possibility of HPV16 L1/L2VLP to be internalized by human peripheral blood leukocytes in ex vivo assays. We have developed a leukocyte separation method from heparinized blood samples aiming cellular integrity and viability. We have expressed humanized L1 and L2 viral capsid proteins in HEK293T epithelial human cells, transiently transfecting them with vectors encoding humanized HPV16 L1 and L2 genes. Recombinant L1/L2 capsid proteins and structured virus-like particles interacted with human peripheral blood mononuclear cells, lymphocytes and monocytes, and were internalized through a pathway involving CD71 transferrin receptors. This was observed, at a percentile of about 54% T- CD4, 47% T-CD8, 48% B-CD20, and 23% for monocytes-CD14. The group of polymorph nuclear cells: neutrophils-eosinophils-basophils group did not internalize any VLPs. Blockage assays with biochemical inhibitors of distinct pathways, like chlorpromazine, rCTB, filipin, nystatin, liquemin, and sodium azide also evidentiated the occurrence of virus-like particles indiscriminate entrance via membrane receptor on mononuclear cells. This study shows that HPV16 L1/L2 VLPs can interact with the plasma membrane surface and successfully enter lymphocytes without requiring a specific receptor. Legend of the Graphical AbstractGraphical abstract showing ex vivo and in vitro internalization between VLPs and host cells. After leukocytes separation from human whole blood, it was performed the identification of human peripheral blood leukocytes in ex vivo interactions with VLPs. The graph shows that of the cells that interacted with VLPs, 52% corresponded to lymphocytes T-CD4, 47% lymphocytes T-CD8, 48% lymphocytes B-CD20, and only 23% of the monocytes CD14 interacted with these particles. However, monocytes apparently internalized larger amounts of particles when compared to lymphocytes. It is probable that in some T lymphocytes the amount of internalized particles has been imperceptible to the confocal microscope, since the VLPs produced in this research are around 50 nm in diameter. These results lead to two important implications. First, the interaction of VLPs with lymphocytes may result in the activation of these cells and, consequently, increase the population of these circulating cells, this being crucial in the induction of specific immune response. In the second implication, these lymphocytes would internalize small amounts of virus, insufficient to activate the immune system. Here it is important to note that lymphocytes are cells capable of dividing and it is estimated that the half-life of these inactive cells in humans is of some years. In addition, as it is known, inactive lymphocytes continually re-circulate through the bloodstream and lymphatic vessels. The percentage of cells that interacted with the HPV16 L1/L2 VLPs was calculated by the number of cells recognized by the anti-CD antibodies, which internalized these particles. The result corresponds to the analysis in duplicates, being representative of at least four tests. All images are original and cells were processed by Cianciarullo AM et al., at the Butantan Institute, Sao Paulo - SP, Brazil. Electron micrographs of human leukocytes, HEK293T and HPV16 L1/L2 VLPs were obtained in a Zeiss EM109 transmission electron microscope. The blue color of the VLPs and colored leukocytes were virtually attributed. Leukocyte and HEK293T present filamentous actin (red) and HPV16 L1/L2 VLPs (green), by fluorescence in a Confocal Zeiss LSM 510 Meta Microscope O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=195 SRC="FIGDIR/small/299214v2_ufig1.gif" ALT="Figure 1"> View larger version (68K): org.highwire.dtl.DTLVardef@1ee89b8org.highwire.dtl.DTLVardef@193d0a6org.highwire.dtl.DTLVardef@1674526org.highwire.dtl.DTLVardef@ecd80d_HPS_FORMAT_FIGEXP M_FIG C_FIG

Explore related subjects

Keep this discovery

BibTeXRIS

Cianciarullo, A. M., Szulczewski, V., Kavati, E. A., Hosoda, T. M., Leao, E., Borelli, P., Boccardo, E., Mueller, M., Karanam, B., Becak, W.. 2018-04-11. Human Papillomavirus Type 16 L1/L2 VLP Experimental Internalisation by Human Peripheral Blood Leukocytes. https://doi.org/10.1101/299214

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Ex vivo human tumor slices more accurately predict patient responses to an oncolytic virus than in vivo mouse models

Immunotherapies, including oncolytic viruses (OV), are promising therapies that can enhance anti-tumor immune responses. However, preclinical success of immunotherapies in mouse models has not always translated to clinical benefit in cancer patients. This study compared preclinical efficacy and mechanism of action for ASP9801, a vaccinia virus expressing IL-7 and IL-12, using mouse models of colorectal cancer (CRC) in vivo and in human organotypic tumor slice models ex vivo. The murine surrogate for ASP9801 significantly reduced tumor volumes in treated and abscopal tumors in two different CRC models in vivo (MC38 and RO100). Treatment efficacy was accentuated when combined with anti-PD1 treatment, and single-cell RNA sequencing analysis revealed depletion of tumor cells and increased T cell infiltration and activation in both treated and abscopal tumors. However, human tissue analysis ex vivo (E-slices) using PDX models and patient samples showed that ASP9801 is not effective in CRC, consistent with clinical trial results. On the other hand, ASP9801 was highly effective in GBM, indicating indication-specific efficacy of ASP9801, and how E-slice assays can be used to identify treatment-sensitive indications. This study demonstrates the superiority of E-slices over mouse models for predicting clinical response and its utility in planning clinical trials.

cancer biology

Immune-cell depleted diffuse large B-cell lymphomas have reduced expression of MHC class I

Immunotherapy has transformed treatment for many cancers. In the aggressive and genetically heterogeneous diffuse large B-cell lymphoma (DLBCL), CD19 CAR T-cell therapy is highly effective, whereas immune checkpoint blockade has shown limited benefit. Loss of MHC expression is a common mechanism to escape T-cell cytotoxicity, and loss of MHC class I (MHC-I) and II are frequent in DLBCL. We applied imaging mass cytometry to diagnostic biopsies from younger, high-risk DLBCL patients to map the tumor microenvironment (TME) spatial architecture in relation to tumor cell MHC expression, mutational status, transcriptomic and proteomic profiles. Neighborhood analyses identified four TME subtypes: immune-cell depleted and three immune-infiltrated types (mixed, CD4 T cell-rich, CD8 T-cell/macrophage-rich). Depleted cases had shorter overall survival (p = 0.033) and increased expression of proteins involved in DNA replication and proliferation markers compared to infiltrated cases. Tumor cell MHC-I expression was heterogeneous. Cases with low frequency of MHC-I-pos tumor cells were enriched for the depleted TME type. MHC-I-pos tumor cells were surrounded by CD4 and CD8 T cells and M1 macrophages, whereas MHC-I-neg tumor cells were closer to other MHC-I-neg tumor cells. These findings suggest that TME-based classification incorporating tumor cell MHC-I status may improve individualized immunotherapy selection.

cancer biology

Cross-species analysis links cell-cell communication rewiring to NOTCH2 during serous endometrial carcinogenesis

Cell-cell interactions shape the fate of mutant cells during cancer initiation but how these interactions evolve during progression to pathologically recognizable lesions remain poorly understood. Here, we investigated cell-cell communication during serous endometrial carcinoma (SEC; also known as uterine serous carcinoma) development using a lineage-traceable mouse model and cross-species analyses of the mouse and human neoplastic endometrium. In mice, the early, pre-dysplastic stage was marked by a global decrease in inferred cell-cell interactions, followed by extensive communication network rewiring during neoplastic progression. Pathway-specific analysis revealed a similar pattern for NOTCH signaling, with NOTCH2 emerging as the dominant NOTCH receptor in Trp53/Rb1-mutant immature epithelial cells. Functionally, NOTCH2 promoted the outgrowth of more proliferative mutant organoids. Cross-species transcriptomic analysis identified conserved immature epithelial states in mouse and human neoplastic endometrial epithelium. In human tissues, NOTCH2 was overexpressed in serous endometrial intraepithelial carcinoma, a precursor of SEC, and in overt SEC. Furthermore, elevated NOTCH2 expression was associated with poor patient survival. These findings link cell-cell communication rewiring during experimental SEC development to conserved neoplastic epithelial states and identify NOTCH2 as an early marker and a potential target of disease interception.

cancer biology